Newton biotech with drug to treat recurring kidney stones gets $25M

A Newton biotech that launched three years ago with a $15 million venture capital investment is today announcing a second round of $25 million to bring its potential drug to treat recurring kidney stones and other renal disease to late-stage clinical trials...